<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Examples of common drug interactions of immunosuppressants used in solid-organ transplant: Cyclosporine, tacrolimus, sirolimus, and everolimus</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Examples of common drug interactions of immunosuppressants used in solid-organ transplant: Cyclosporine, tacrolimus, sirolimus, and everolimus</h1>
<div class="graphic"><div class="figure"><div class="ttl">Examples of common drug interactions of immunosuppressants used in solid-organ transplant: Cyclosporine, tacrolimus, sirolimus, and everolimus</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Common types of drug interactions</td> <td class="subtitle1">Examples of interacting drugs</td> <td class="subtitle1">Approach to management in the absence of appropriate noninteracting alternatives</td> </tr> <tr> <td>Coadministration of drugs that inhibit CYP3A metabolism and/or P-gp efflux can <strong>increase immunosuppressant serum concentrations</strong>, leading to significant toxicities.</td> <td> <ul> <li>Amiodarone</li> <li>ART-boosting agents (eg, ritonavir, cobicistat)</li> <li>Azole antifungals (eg, fluconazole, posaconazole, voriconazole)</li> <li>HIV protease inhibitors (eg, atazanavir, nelfinavir, saquinavir)</li> <li>Macrolide antibiotics</li> <li>Non-dihydropyridine calcium channel blockers</li> <li>Ombitasvir-paritaprevir-ritonavir with or without dasabuvir (an HCV, direct-acting antiviral regimen)</li> <li>Grapefruit juice</li> </ul> </td> <td> <ul> <li>Closely monitor immunosuppressant concentrations and signs of toxicity (eg, tremors and headaches).</li> <li>Substantial, including preemptive, dose reduction of immunosuppressant drug may be needed (eg, on average, only 25% of the standard dose of cyclosporine is required if administered concomitantly with HIV protease inhibitors).</li> <li>Some combinations are considered contraindicated according to product labeling; refer to appropriate topic reviews for detail.</li> <li>Lists of CYP3A and P-gp <strong>inhibitors</strong> are provided as separate tables within UpToDate.</li> </ul> </td> </tr> <tr> <td>Coadministration of drugs that induce CYP3A metabolism and/or P-gp efflux pumping can <strong>decrease immunosuppressant serum concentrations</strong>, increasing the risk of organ rejection.</td> <td> <ul> <li>Antiseizure medications, enzyme inducing (eg, carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)</li> <li>Enzalutamide</li> <li>Nafcillin</li> <li>Rifamycins (eg, rifabutin, rifampin, rifapentine)</li> <li>St. John's wort</li> </ul> </td> <td> <ul> <li>Closely monitor immunosuppressant serum concentrations and signs of organ rejection.</li> <li>Significant immunosuppressant dose increases may be needed.</li> <li>Enzyme induction can require up to 2 weeks to achieve maximum effect and persists for up to 2 weeks after discontinuation of the interacting medication. Clinically significant effects can occur within hours to days of starting a CYP inducer.</li> <li>Lists of CYP3A and P-gp <strong>inducers</strong> are provided as separate tables within UpToDate.</li> </ul> </td> </tr> <tr> <td>Coadministration of nephrotoxic drugs with cyclosporine or tacrolimus can cause <strong>additive or synergistic kidney injury</strong>.</td> <td> <ul> <li>Aminoglycosides</li> <li>Amphotericin B</li> <li>Nonsteroidal antiinflammatory drugs (NSAIDs)</li> </ul> </td> <td> <ul> <li>Concomitant administration of cyclosporine and tacrolimus with other potentially nephrotoxic drugs should be avoided.</li> <li>Suggested dose adjustments for use with colchicine are available in the <a href="https://www.uptodate.com/drug-interactions">drug interactions program</a> database included within UpToDate.</li> </ul> </td> </tr> <tr> <td>Coadministration of drugs that increase serum potassium with cyclosporine or tacrolimus may cause <strong>severe hyperkalemia</strong>.</td> <td> <ul> <li>ACE inhibitors/ARBs</li> <li>Amiloride</li> <li>Spironolactone</li> <li>Triamterene</li> <li>Trimethoprim, trimethoprim-sulfamethoxazole (cotrimoxazole)</li> </ul> </td> <td> <ul> <li>Closely monitor serum potassium levels.</li> </ul> </td> </tr> <tr> <td>Coadministration of cyclosporine (not tacrolimus) with mTOR inhibitors can <strong>increase the concentration and toxicity</strong> of mTOR inhibitors.</td> <td> <ul> <li>Sirolimus</li> <li>Everolimus</li> </ul> </td> <td> <ul> <li>Separate administration of sirolimus from cyclosporine by 4 hours; give sirolimus at a consistent time with respect to cyclosporine.</li> <li>Closely monitor immunosuppressant serum concentrations.</li> </ul> </td> </tr> <tr> <td>Coadministration of statin drugs with cyclosporine can <strong>increase statin levels and risk of myotoxicity</strong>.</td> <td> <ul> <li>Atorvastatin</li> <li>Lovastatin</li> <li>Pitavastatin</li> <li>Rosuvastatin</li> <li>Simvastatin</li> </ul> </td> <td> <ul> <li>Pravastatin and fluvastatin are preferred due to decreased interactions.</li> <li>Tacrolimus may be preferred over cyclosporine in patients receiving statin therapy.</li> <li>Cyclosporine and simvastatin should not be used together.</li> <li>Some combinations are considered contraindicated or statin daily dose limits are recommended in the product labeling; refer to the <a href="https://www.uptodate.com/drug-interactions">drug interactions program</a> database included within UpToDate for detailed information.</li> </ul> </td> </tr> <tr> <td>Coadministration of cyclosporine with colchicine can <strong>increase the risk of colchicine neuromyopathy</strong>.</td> <td> <ul> <li>Colchicine</li> </ul> </td> <td> <ul> <li>Concomitant administration of cyclosporine and colchicine should be avoided.</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><ul>
<li><strong>Important note:</strong> The interactions listed in this table illustrate some of the common types of interactions with immunosuppressive drugs; this is <strong>not</strong> a complete list, and many other significant drug interactions can occur. When initiating or altering drug therapy, use of a drug interactions database, such as the <a href="https://www.uptodate.com/drug-interactions">drug interactions program</a> included within UpToDate, is advised.</li>
<li>Cyclosporine, tacrolimus, sirolimus, and everolimus are highly dependent upon CYP3A metabolism for clearance and are also substrates of P-gp drug efflux pump. Some interactions can lead to subtherapeutic or dangerously toxic levels of immunosuppressant concentrations.</li>
<li>When appropriate noninteracting alternatives are readily available, consider modifying treatment to avoid combined use with potent metabolic inhibitors/inducers or agents known to have additive toxicities with immunosuppressants.</li>
<li>Drug therapy should be managed by transplant specialists with expertise in therapeutic drug monitoring, and doses should be adjusted based upon measurement of immunosuppressant concentrations, particularly whenever drug therapy is altered. If there are any concerns about the safety of a given medication or supplement, they should be discussed with the patient's transplant center prior to initiation.</li>
</ul></div><div class="graphic_footnotes">ACE: angiotensin-converting enzyme; ARB: angiotensin II receptor blocker; ART: HIV antiretroviral therapy; CYP: cytochrome P450 metabolism; HCV: hepatitis C virus; HIV: human immunodeficiency virus; mTOR: mechanistic (mammalian) target of rapamycin; P-gp: P-glycoprotein drug efflux pump.</div><div class="graphic_reference">Prepared with data from Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</div><div id="graphicVersion">Graphic 110436 Version 21.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
